Key Insights

Highlights

Success Rate

64% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

12.1%

4 terminated out of 33 trials

Success Rate

63.6%

-22.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

71%

5 of 7 completed with results

Key Signals

5 with results64% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (8)
Early P 1 (2)
P 1 (9)
P 2 (6)

Trial Status

Recruiting8
Completed7
Unknown6
Terminated4
Withdrawn3
Enrolling By Invitation2

Trial Success Rate

63.6%

Benchmark: 86.6%

Based on 7 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT02390752Phase 1Recruiting

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

NCT07499128Not ApplicableEnrolling By Invitation

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

NCT07522905Not ApplicableRecruitingPrimary

Virtual Buddy Movement Therapy for Psychomotor and Social Development in Pediatric Oncology Patients in Remission

NCT06539338Phase 1Active Not Recruiting

A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

NCT07469592Not ApplicableNot Yet Recruiting

eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

NCT05968963Not ApplicableActive Not Recruiting

Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation

NCT06765876Early Phase 1Recruiting

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

NCT06387121Phase 2RecruitingPrimary

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

NCT06709469Phase 1RecruitingPrimary

Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

NCT05660473Phase 2RecruitingPrimary

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

NCT03384654Phase 2CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT06560879Phase 2Enrolling By Invitation

Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children with Leukemia

NCT03743246Phase 1TerminatedPrimary

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT05873322RecruitingPrimary

Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma

NCT01386619Phase 1Completed

NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

NCT06237192Not ApplicableRecruitingPrimary

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

NCT04456959CompletedPrimary

InO - A Retrospective Study of UK Patients With Leukaemia

NCT05024357Not ApplicableUnknownPrimary

A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL

NCT05026229Not ApplicableUnknownPrimary

A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

NCT03545659CompletedPrimary

Childhood Acute Lymphoblastic Leukaemia: Follow-Up

Scroll to load more

Research Network

Activity Timeline